CLINICAL TRIALS PROFILE FOR FLUDEOXYGLUCOSE F18
✉ Email this page to a colleague
All Clinical Trials for FLUDEOXYGLUCOSE F18
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001568 ↗ | Phase II Study of the Role of Anti-CEA Antibody Immunoscintigraphy & Positron Emission Tomography in the Localization of Recurrent Colorectal Carcinoma in Patients With Rising Serum CEA Levels in the Absence of Imageable Disease by Conventional Moda | Completed | National Cancer Institute (NCI) | Phase 2 | 1997-02-01 | Positron Emission Tomography (PET scanning) is performed using a total dose of less than 50 mRad per patient visit. Fludeoxyglucose F 18 (FDG) is injected intravenously over 2 min. Initial dynamic images will be obtained over the heart. Emission imaging will work from the midcervical region down to the perineal region. For CEA scanning, radiolabeled antibody, arcitumomab (IMMU-4), is injected intravenously over 5 min. A single photon emission computed tomography (SPECT) transmission scan is performed over the same regions as the emission scans. Total dose from transmission scans should be no more than 20 mRad per patient visit. Patients then undergo exploratory laparotomy performed by two surgeons, one blinded to the results of the CEA-Scan and PET scan. At the completion of all exploration, all identified disease is biopsied for pathologic analysis and any resectable disease is removed. Patients are followed every 3 months for 1 year, every 6 months for the second year, and then after 3 years. |
| NCT00004152 ↗ | PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma | Completed | National Cancer Institute (NCI) | Phase 2 | 1999-02-01 | RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease in patients who have stage III or stage IV melanoma. |
| NCT00004152 ↗ | PET and CT Scans to Evaluate Patients With Stage III or Stage IV Melanoma | Completed | Memorial Sloan Kettering Cancer Center | Phase 2 | 1999-02-01 | RATIONALE: Diagnostic procedures may improve the ability to detect metastatic melanoma and to determine the extent of disease. PURPOSE: Phase II trial to evaluate the effectiveness of PET and CT scans to detect metastatic disease in patients who have stage III or stage IV melanoma. |
| NCT00004867 ↗ | Positron Emission Tomography in Determining Stage of Esophageal Cancer | Completed | National Cancer Institute (NCI) | N/A | 1999-11-01 | RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer. |
| NCT00004867 ↗ | Positron Emission Tomography in Determining Stage of Esophageal Cancer | Completed | Alliance for Clinical Trials in Oncology | N/A | 1999-11-01 | RATIONALE: Imaging procedures such as positron emission tomography may improve the ability to determine the stage of esophageal cancer. PURPOSE: This clinical trial is studying how well fludeoxyglucose F 18 positron emission tomography determines tumor stage in patients with esophageal cancer. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for FLUDEOXYGLUCOSE F18
Condition Name
Clinical Trial Locations for FLUDEOXYGLUCOSE F18
Trials by Country
Clinical Trial Progress for FLUDEOXYGLUCOSE F18
Clinical Trial Phase
Clinical Trial Sponsors for FLUDEOXYGLUCOSE F18
Sponsor Name
